Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Equity Average (2022 - 2025)

BioXcel Therapeutics has reported Equity Average over the past 4 years, most recently at -$92.2 million for Q4 2025.

  • Quarterly results put Equity Average at -$92.2 million for Q4 2025, down 3.16% from a year ago — trailing twelve months through Dec 2025 was -$92.2 million (down 3.16% YoY), and the annual figure for FY2025 was -$94.3 million, down 26.04%.
  • Equity Average for Q4 2025 was -$92.2 million at BioXcel Therapeutics, up from -$98.3 million in the prior quarter.
  • Over the last five years, Equity Average for BTAI hit a ceiling of $179.1 million in Q2 2022 and a floor of -$98.9 million in Q2 2025.
  • Median Equity Average over the past 4 years was -$64.4 million (2024), compared with a mean of -$15.5 million.
  • Biggest five-year swings in Equity Average: plummeted 360.32% in 2024 and later dropped 3.16% in 2025.
  • BioXcel Therapeutics' Equity Average stood at $101.9 million in 2022, then crashed by 147.66% to -$48.6 million in 2023, then crashed by 84.04% to -$89.4 million in 2024, then fell by 3.16% to -$92.2 million in 2025.
  • The last three reported values for Equity Average were -$92.2 million (Q4 2025), -$98.3 million (Q3 2025), and -$98.9 million (Q2 2025) per Business Quant data.